A Phase 3 interventional study of ZOSTAVAX™ (concomitant) and Comparator: Influenza Vaccine in Herpes Zoster, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-09-21.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing Chickenpox Vaccine in Herpes Zoster — none open to participants now, none under way, none of them phase 3. Chickenpox Vaccine · Herpes Zoster.
Among the 29 studies testing Chickenpox Vaccine in Herpes Zoster, this one is the 4th largest by enrollment, is the only one that started in 2005, is one of 9 in phase 3, and was the 2nd registered.
299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.
Browse Herpes Zoster studies →None of the 29 studies testing Chickenpox Vaccine in Herpes Zoster is open now. The open studies under Herpes Zoster, anywhere →
Chickenpox Vaccine: first FDA approval 1995 (Varivax). What it is approved for, and how studies give it, is on its page →
Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.
This study: 50 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 9 · Phase 4 8
First in 2001; this study’s year is marked. 1 started in 2005.
This study's enrollment of 763 is above the median of 160 across 247 interventional studies indexed under Herpes Zoster.
Median enrollment 160 across the 29 interventional studies. Of the 28 that completed or were terminated, 20 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 29 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
27 studies in Herpes Zoster by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 26 finished, 24 (92%) have results posted.
Among the 27 studies in Herpes Zoster by Merck & Co., Inc, this one is the 6th largest by enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2005, is one of 14 in phase 3, and was the 3rd registered.
Merck & Co., Inc’s Herpes Zoster studies by the year they started, since 1995.
None of the studies under way reaches primary completion within a year.
Among the 29 studies testing Chickenpox Vaccine in Herpes Zoster, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 27 in Herpes Zoster:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether the investigational zoster vaccine has a comparable immune response (the body's ability to protect against disease) and safety profile when given concomitantly with another vaccine.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Zostavax concomitantly with influenza vaccine on Day 1, placebo at week 4
Biological: ZOSTAVAX™ (concomitant) · Biological: Comparator: Influenza Vaccine
Influenza vaccine and Zostavax placebo on Day 1, Zostavax at week 4
Biological: Comparator: Influenza Vaccine · Biological: ZOSTAVAX™ (Nonconcomitant)
a single administration of 0.65 mL subcutaneous injection of zoster vaccine live on Day 1 and placebo at Week 4
Also known as: V211
a single administration of 0.5 mL intramuscular injection of influenza vaccine (inactivated) at Day 1
Also known as: Fluzone, Vaxigrip
Placebo injection on Day 1 and a single administration of 0.65 mL subcutaneous injection of zoster vaccine live at Week 4
Varicella-zoster Virus (VZV) Glycoprotein Enzyme-linked Immunosorbent Assay (gpELISA) Antibody Responses
The Geometric mean titer (GMT) of the VZV glycoprotein enzyme-linked immunosorbent assay (gpELISA) antibody responses at Week 4 postvaccination in participants who received ZOSTAVAX™ concomitantly with influenza vaccine was compared to that in subjects who received influenza vaccine and ZOSTAVAX™ nonconcomitantly.
Time frame: 4 weeks
Geometric Mean Fold Rise (GMFR) in VZV gpELISA Antibody Titers From Prevaccination to 4 Weeks Postvaccination
GMFR of the VZV gpELISA antibody titers from prevaccination to 4 weeks postvaccination when ZOSTAVAX™ is administered concomitantly with influenza vaccine
Time frame: prevaccination to 4 weeks postvaccination
Geometric Mean Titers (GMTs) of H1N1 Strain Antibody Responses at 4 Weeks Postvaccination
GMT of the H1N1 strain antibody responses at 4 weeks postvaccination in participants who receive ZOSTAVAX™ concomitantly with influenza vaccine and those who receive ZOSTAVAX™ and influenza vaccine nonconcomitantly
Time frame: 4 weeks postvaccination
GMTs of H3N2 Strain Antibody Responses at 4 Weeks Postvaccination
GMT of the H3N2 strain antibody responses at 4 weeks postvaccination in participants who receive ZOSTAVAX™ concomitantly with influenza vaccine and those who receive ZOSTAVAX™ and influenza vaccine nonconcomitantly
Time frame: 4 weeks postvaccination
GMTs of B Strain Antibody Responses at 4 Weeks Postvaccination
GMT of the B strain antibody responses at 4 weeks postvaccination in participants who receive ZOSTAVAX™ concomitantly with influenza vaccine and those who receive ZOSTAVAX™ and influenza vaccine nonconcomitantly
Time frame: 4 weeks postvaccination
Participants were recruited at 13 sites in the United States and 7 sites in Europe. First Patient In (FPI): 23-SEP-2005; Last Patient Last Visit (LPLV): 08-MAR-2006
| Milestone | Concomitant Group | Nonconcomitant Group |
|---|---|---|
| Started | 382 | 381 |
| Vaccinated at visit 1 | 382 | 380 |
| Vaccinated at visit 2 | 369 | 371 |
| Completed | 366 | 369 |
| Not completed | 16 | 12 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Lost to follow-up | 8 | 5 |
| Withdrew: Protocol violation | 2 | 3 |
| Withdrew: Withdrawal by subject | 3 | 3 |
| Withdrew: Other | 2 | 1 |
The Geometric mean titer (GMT) of the VZV glycoprotein enzyme-linked immunosorbent assay (gpELISA) antibody responses at Week 4 postvaccination in participants who received ZOSTAVAX™ concomitantly with influenza vaccine was compared to that in subjects who received influenza vaccine and ZOSTAVAX™ nonconcomitantly.
| gpELISA units/mL | Concomitant Group | Nonconcomitant Group |
|---|---|---|
| Varicella-zoster Virus (VZV) Glycoprotein Enzyme-linked Immunosorbent Assay (gpELISA) Antibody Responses | 553.5 (499.0 to 613.9) | 588.7 (531.9 to 651.5) |
GMFR of the VZV gpELISA antibody titers from prevaccination to 4 weeks postvaccination when ZOSTAVAX™ is administered concomitantly with influenza vaccine
| ratio | Concomitant Group |
|---|---|
| Geometric Mean Fold Rise (GMFR) in VZV gpELISA Antibody Titers From Prevaccination to 4 Weeks Postvaccination | 2.1 (2.0 to 2.3) |
GMT of the H1N1 strain antibody responses at 4 weeks postvaccination in participants who receive ZOSTAVAX™ concomitantly with influenza vaccine and those who receive ZOSTAVAX™ and influenza vaccine nonconcomitantly
| titers | Concomitant Group | Nonconcomitant Group |
|---|---|---|
| Geometric Mean Titers (GMTs) of H1N1 Strain Antibody Responses at 4 Weeks Postvaccination | 122.9 (107.8 to 140.0) | 134.2 (118.3 to 152.2) |
GMT of the H3N2 strain antibody responses at 4 weeks postvaccination in participants who receive ZOSTAVAX™ concomitantly with influenza vaccine and those who receive ZOSTAVAX™ and influenza vaccine nonconcomitantly
| titers | Concomitant Group | Nonconcomitant Group |
|---|---|---|
| GMTs of H3N2 Strain Antibody Responses at 4 Weeks Postvaccination | 162.7 (140.4 to 188.4) | 150.5 (129.8 to 174.5) |
GMT of the B strain antibody responses at 4 weeks postvaccination in participants who receive ZOSTAVAX™ concomitantly with influenza vaccine and those who receive ZOSTAVAX™ and influenza vaccine nonconcomitantly
| titers | Concomitant Group | Nonconcomitant Group |
|---|---|---|
| GMTs of B Strain Antibody Responses at 4 Weeks Postvaccination | 119.8 (104.8 to 137.1) | 136.5 (120.5 to 154.7) |
Collected over Day 1-28 following each vaccination. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Concomitant Group | — | 6/378 (1.6%) | 199/378 (52.6%) |
| Nonconcomitant Group | — | 5/376 (1.3%) | 181/376 (48.1%) |
| Event | Concomitant Group | Nonconcomitant Group |
|---|---|---|
| Cardiac failure congestiveCardiac disorders | 3/378 | 0/376 |
| AnaemiaBlood and lymphatic system disorders | 0/378 | 1/376 |
| Angina unstableCardiac disorders | 0/378 | 1/376 |
| AppendicitisInfections and infestations | 0/378 | 1/376 |
| Upper limb fractureInjury, poisoning and procedural complications | 0/378 | 1/376 |
| Back painMusculoskeletal and connective tissue disorders | 0/378 | 1/376 |
| Aortic valve stenosisCardiac disorders | 1/378 | 0/376 |
| ArrhythmiaCardiac disorders | 1/378 | 0/376 |
| Myocardial infarctionCardiac disorders | 1/378 | 0/376 |
| PneumoniaInfections and infestations | 1/378 | 0/376 |
| Event | Concomitant Group | Nonconcomitant Group |
|---|---|---|
| Injection Site Erythema (ZOSTAVAX™ injection site)General disorders | 125/378 | 101/376 |
| Injection Site Pain (ZOSTAVAX™ injection site)General disorders | 114/378 | 107/376 |
| Injection Site Swelling (ZOSTAVAX™ injection site)General disorders | 70/378 | 94/376 |
| Injection Site Pain (Influenza vaccine injection site)General disorders | 90/378 | 86/376 |
| Injection Site Erythema (Influenza vaccine injection site)General disorders | 46/378 | 29/376 |
| Injection Site Swelling (Influenza vaccine injection site)General disorders | 41/378 | 31/376 |
| Injection Site Pain (Placebo injection site)General disorders | 16/378 | 23/376 |
| Injection Site Erythema (Placebo injection site)General disorders | 11/378 | 19/376 |
| Upper respiratory tract infectionInfections and infestations | 19/378 | 17/376 |
| Age, Continuous(years) | Concomitant Group | Nonconcomitant Group | Total |
|---|---|---|---|
| Mean | 63.4 ± 7.99 | 63.6 ± 8.24 | 63.5 ± 8.11 |
| Sex: Female, Male(Participants) | Concomitant Group | Nonconcomitant Group | Total |
|---|---|---|---|
| Female | 215 | 212 | 427 |
| Male | 167 | 168 | 335 |
| Race/Ethnicity, Customized(participants) | Concomitant Group | Nonconcomitant Group | Total |
|---|---|---|---|
| African | 1 | 0 | 1 |
| Asian | 5 | 4 | 9 |
| Black | 106 | 100 | 206 |
| Hispanic American | 11 | 11 | 22 |
| Indian | 0 | 1 | 1 |
| Multiracial | 0 | 2 | 2 |
| Native American | 1 | 1 | 2 |
| White | 258 | 261 | 519 |
No study locations are listed for this record.
The record gives a start of Sep 2005, a primary completion of Mar 2006 and a completion of Mar 2006. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2010, 4 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Chickenpox Vaccine